Pathogenica, Illumina in co-marketing deal
Wednesday, July 17, 2013
Pathogenica, a provider of medical diagnostic sequencing services and products, and Illumina have agreed to co-market in the Asia Pacific region a new version of Pathogenica’s HAI BioDetection kit compatible with Illumina’s MiSeq benchtop sequencing system. The combined solution will enable users to identify an expanded panel of bacteria and drug resistance genes present within clinical specimens and mixed cultures or isolates.
The kit will be a research-use-only test that enables identification and sub-typing of bacterial species responsible for over 95% of hospital acquired infections. The solution provides sequence-level resolution with automated analysis software in a multiplexed assay that makes hospital-wide surveillance practical. The solution has the capability to bypass the requirement of bacterial isolation and culture, expediting workflow, and can process 24-48 samples simultaneously per sequencing run.
“The introduction of an Illumina-compatible version of our kit emphasizes the platform-agnostic flexibility of our technology and allows us to reach new users in the large number of clinical-facing facilities keen to use Illumina’s sequencing technology,” said Yemi Adesokan, chief executive officer of Pathogenica.